Thanks to Fen Castro of VirtueInsight, Director for inviting me to 9th Biosimilars Congregation 2016., Lalit hotel, Mumbai, India, 22nd Sept 2016……..http://www.virtueinsight.com/pharma/9th-Biosimilars-Congregation-2016/
with Fen Castro of VirtueInsight, Director , and his team , , —thanks for inviting me to 9th Biosimilars Congregation 2016., Lalit hotel, Mumbai, India, 22nd Sept 2016 — with Fen Castro and Virtue Insight at The Lalit Hotel.
with Fen Castro of VirtueInsight, Director ,at 9th Biosimilars Congregation 2016., Lalit hotel, Mumbai, India, 22nd Sept 2016 also in pic DR PAWAN SAHARAN, CHAIRMAN, CEO BIOMIX — with Fen Castro and Virtue Insight.
With SWATI PATEL AND SUSHIL MOMAYA OF ADVINUS THERAPEUTICS at 9th Biosimilars Congregation 2016., Lalit hotel, Mumbai, India, 22nd Sept 2016 — with Sushil K. Momaya, Swati Patel and Virtue Insight at Hotel Lalit.
This 9th Biosimilars Congregation 2016 brings together scientists, researchers and CROs from around the world. Biologics are a highly effective class of medicines that are based on naturally occurring proteins and produced using living cells. Current concepts of drugs and biologics, Unique considerations for biologics, Early clinical development essentials, Cancer therapeutics, Comparability for Biologics, Biosimilar approvals are the points of discussion in this session.
9th Biosimilars Congregation 2016 conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. Hence, this global event will look at the multiple facets of biosimilars, ranging from the evolving regulatory landscapes, biosimilar guidelines to the legal and economic aspects and current challenges in biosimilar development. This biosimilar conference will focus on multiple aspects of biosimilar product development to successfully deliver safe, biosimilar products to the market place. By attending this biologics conference you will gain a comprehensive outlook on the key issues surrounding biosimilars. This event will provide an important platform for biosimilars stakeholders to discuss and share best practices in expediting development in Biosimilars 2016 and onwards.